UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Holdings in OPKO Health, Inc. (NASDAQ:OPK)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 19.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 605,058 shares of the biotechnology company’s stock after selling 149,104 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.09% of OPKO Health worth $902,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. CIBC Asset Management Inc increased its holdings in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares in the last quarter. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the last quarter. Algert Global LLC bought a new stake in shares of OPKO Health in the second quarter worth approximately $44,000. Private Advisor Group LLC raised its holdings in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Ground Swell Capital LLC bought a new position in OPKO Health during the third quarter valued at approximately $63,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction dated Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, with a total value of $162,000.00. Following the completion of the purchase, the chief executive officer now directly owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased a total of 1,304,255 shares of company stock worth $2,024,605 over the last quarter. 47.26% of the stock is currently owned by corporate insiders.

OPKO Health Trading Up 0.6 %

Shares of OPK stock opened at $1.57 on Friday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -8.26 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a fifty day moving average price of $1.54 and a 200-day moving average price of $1.48. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.76.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Wednesday. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.